Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 22, Issue 2, 2016, Pages 307-315

  Jodele, Sonata ^a   Fukuda, Tsuyoshi ^a   Mizuno, Kana ^a   Vinks, Alexander A ^a   Laskin, Benjamin L ^b   Goebel, Jens ^a   Dixon, Bradley P ^a   Chima, Ranjit S ^a   Hirsch, Russel ^a   Teusink, Ashley ^a   Lazear, Danielle ^a   Lane, Adam ^a   Myers, Kasiani C ^a   Dandoy, Christopher E ^a   Davies, Stella M ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

CH50; Complement; Eculizumab; Membrane attack complex; SC5b 9; Thrombotic microangiopathy

Indexed keywords

CYCLOSPORIN; ECULIZUMAB; MONOCLONAL ANTIBODY;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT HEMOLYSIS TEST; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG MONITORING; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; OVERALL SURVIVAL; PHARMACODYNAMICS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; ADVERSE EFFECTS; METABOLIC CLEARANCE RATE; THROMBOTIC MICROANGIOPATHIES; TRANSPLANTATION CONDITIONING;

ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; METABOLIC CLEARANCE RATE; THROMBOTIC MICROANGIOPATHIES; TRANSPLANTATION CONDITIONING;

EID: 84958628313     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.10.002     Document Type: Article

References (33)

1. Jodele S., Laskin B.L., Dandoy C.E., et al. A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev 2014, 29:191-204.
2. de Fontbrune F.S., Galambrun C., Sirvent A., et al. Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: A study from the SFGM-TC. Transplantation 2015, 99:1953-1959.
3. Kim S.S., Patel M., Yum K., Keyzner A. Hematopoietic stem cell transplant-associated thrombotic microangiopathy: review of pharmacologic treatment options. Transfusion 2015, 55:452-458.
4. Labrador J., Lopez-Corral L., Lopez-Godino O., et al. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus. Bone Marrow Transplant 2014, 49:684-690.
5. Cho B.S., Yahng S.A., Lee S.E., et al. Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation. Transplantation 2010, 90:918-926.
6. Jodele S., Davies S.M., Lane A., et al. Refined diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a prospective study in children and young adults. Blood 2014, 124:645-653.
7. Laskin B.L., Maisel J., Goebel J., et al. Renal arteriolar C4d deposition: A novel characteristic of hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Transplantation 2013, 96:217-223.
8. Jodele S., Licht C., Goebel J., et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood 2013, 122:2003-2007.
9. Ricklin D., Cines D.B. TMA: beware of complements. Blood 2013, 122:1997-1999.
10. Ricklin D., Lambris J.D. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol 2013, 190:3831-3838.
11. Meri S. Complement activation in diseases presenting with thrombotic microangiopathy. Eur J Intern Med 2013, 24:496-502.
12. Kojouri K., George J.N. Thrombotic microangiopathy following allogeneic hematopoietic stem cell transplantation. Curr Opin Oncol 2007, 19:148-154.
13. Nakamae H., Yamane T., Hasegawa T., et al. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation. Am J Hematol 2006, 81:525-531.
14. Willems E., Baron F., Seidel L., et al. Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning. Bone Marrow Transplant 2010, 45:689-693.
15. Uderzo C., Bonanomi S., Busca A., et al. Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Transplantation 2006, 82:638-644.
16. Jodele S., Davies S.M., Lane A., et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood 2014, 124:645-653.
17. Jodele S., Fukuda T., Vinks A., et al. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant 2014, 20:518-525.
18. Schmidtko J., Peine S., El-Housseini Y., et al. Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab. Am J Kidney Dis 2013, 61:289-299.
19. Shah N., Rutherford C., Matevosyan K., et al. Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP). Br J Haematol 2013, 163:514-519.
20. Legendre C.M., Licht C., Muus P., et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013, 368:2169-2181.
21. Legendre C.M., Licht C., Loirat C. Eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013, 369:1379-1380.
22. Peffault de Latour R., Fremeaux-Bacchi V., Porcher R., et al. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood 2015, 125:775-783.
23. Prasad K., Karlupia N. Prevention of bacterial meningitis: an overview of Cochrane systematic reviews. Respir Med 2007, 101:2037-2043.
24. Youden W.J. Index for rating diagnostic tests. Cancer 1950, 3:32-35.
25. Zheng S., Gaitonde P., Andrew M.A., et al. Model-based assessment of dosing strategies in children for monoclonal antibodies exhibiting target-mediated drug disposition. Pharmacometr Syst Pharmacol 2014, 3:e138.
26. Anderson B.J., Holford N.H. Tips and traps analyzing pediatric PK data. Paediatr Anaesth 2011, 21:222-237.
27. Keating G.M. Eculizumab: a review of its use in atypical haemolytic uraemic syndrome. Drugs 2013, 73:2053-2066.
28. McKeage K. Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria. Drugs 2011, 71:2327-2345.
29. van den Born B.J., van der Hoeven N.V., Groot E., et al. Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension. Hypertension 2008, 51:862-866.
30. Feng S., Eyler S.J., Zhang Y., et al. Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome. Blood 2013, 122:1487-1493.
31. Shayani S., Palmer J., Stiller T., et al. Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 2013, 19:298-304.
32. Rachakonda S.P., Penack O., Dietrich S., et al. Single-nucleotide polymorphisms within the thrombomodulin gene (THBD) predict mortality in patients with graft-versus-host disease. J Clin Oncol 2014, 32:3421-3427.
33. Dietrich S., Falk C.S., Benner A., et al. Endothelial vulnerability and endothelial damage are associated with risk of graft-versus-host disease and response to steroid treatment. Biol Blood Marrow Transplant 2013, 19:22-27.